Portfolio Update
INTERNATIONAL BIOTECHNOLOGY TRUST PLC
Portfolio Update as at 28 February 2011
|
Total net assets |
£98.8m |
|
NAV per share |
166.6p |
|
Share price |
147.8p |
|
Total value of unquoted investments |
£23.3m |
|
Total number of portfolio companies |
57 |
|
Cash |
(1)% NAV |
|
Cash committed and reserved to unquoted investments |
9% NAV |
|
Portfolio companies with < 1 year of cash |
16% NAV |
Top Ten Holdings
|
Company Name |
% NAV |
|
Shire Ltd |
5.95 |
|
Celgene |
5.61 |
|
Amgen |
4.91 |
|
Gilead Sciences |
4.91 |
|
Teva |
4.42 |
|
Insulet |
4.21 |
|
Micromet |
3.99 |
|
Cadent |
3.96 |
|
Vertex |
3.26 |
|
Averion |
3.03 |
|
|
----------- |
|
Total |
44.25 |
|
Geographical Allocation |
% |
|
United States |
73 |
|
Europe |
26 |
|
Australia |
2 |
|
Cash |
(1) |
|
|
----------- |
|
Total |
100 |
|
Quoted/Unquoted allocation |
% |
|
Quoted |
77 |
|
Unquoted |
24 |
|
Cash |
(1) |
|
|
----------- |
|
Total |
100 |
BNP Paribas Secretarial Services Limited
Company Secretary
16 MARCH 2011
This information is provided by RNS